Wednesday, July 2, 2025 7/2/2025

Targeted Anchoring Ecto-enzyme on Cancer Cell Surface to Enhance Antibody Therapy in Breast Cancer

Award Number: R21CA267853
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/10/2021
PERIOD OF PERFORMANCE END DATE: 05/31/2025

Group Awards By:

View Award Description

Targeted Anchoring Ecto-enzyme on Cancer Cell Surface to Enhance Antibody Therapy in Breast Cancer - Abstract: Although the anti-HER2 antibody, trastuzumab, has been the mainstay of therapy for HER2+ breast cancer (BC), its clinical benefit remains heterogeneous among HER2+ patients and metastatic HER2+ BC remains generally incurable. The final success of HER2 antibody therapy relies on the induction of anticancer immunity, but this is limited by immunosuppressive mechanisms posed by the tumor microenvironment (TME), resulting in treatment resistance, metastasis, and ultimately lethal BC. Elevated adenosine level is considered a major immunosuppressive mechanism in the TME, causing resistance to trastuzumab by suppressing innate and adaptive antitumor immunity induced by the antibody. Adenosine deaminase (ADA) catalyzes the deamination of adenosine and is capable of reversing immunosuppressive activities of adenosine. However, systemic ADA administration causes toxicity in normal tissues, where adenosine protects the host from excessive immune activation. We hypothesize that targeted anchoring of ADA on HER2+ BC cell surface reprograms immunometabolism in the TME, enhancing the efficacy and safety of HER2-directed immunotherapy. We have developed a highly cancer specific targeting approach to deliver ADA to the surface of HER2+ BC cells. Targeted ADA delivery with an anti-HER2 antibody led to localization of ADA on the cell surface of HER2+ BC cells, and the surface-anchored ADA was capable of depleting adenosine. In tumor-bearing syngeneic mice, HER2-targeted delivery resulted in 5.6-fold increase in tumoral ADA level compared to free ADA administration. Targeted ADA delivery led to TME reprograming into an immunostimulatory landscape and resulted in immune-mediated tumor regression. In the proposed studies, we will elucidate the mechanisms of TME reprograming by surface ADA anchoring (Aim 1) and will develop an approach to enhance surface ADA anchoring by combination with a tyrosine kinase inhibitor (Aim 2). This project can be directly translated into a targeted cancer immunotherapy to treat patients with HER2+ BC. By addressing lack of disease specificity, a main obstacle to the development of next-generation immunotherapeutic regimens, we will contribute to the use of precision medicine for cancer immunotherapy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	WAKE FOREST UNIVERSITY HEALTH SCIENCES	MEDICAL CENTER BLVD	WINSTON SALEM	NC	27157	FORSYTH	USA	Cancer Treatment Research	000	2	11/26/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $177,534 )
2023	2023	WAKE FOREST UNIVERSITY HEALTH SCIENCES	MEDICAL CENTER BLVD	WINSTON SALEM	NC	27157	FORSYTH	USA	Cancer Treatment Research	001	2	3/15/2023	NON-COMPETING CONTINUATION	$14,493
2023	2023	WAKE FOREST UNIVERSITY HEALTH SCIENCES	MEDICAL CENTER BLVD	WINSTON SALEM	NC	27157	FORSYTH	USA	Cancer Treatment Research	000	2	11/21/2022	NON-COMPETING CONTINUATION	$163,041
														Subtotal = $177,534

Issue Date FY: 2022 ( Subtotal = $217,388 )
2022	2022	WAKE FOREST UNIVERSITY HEALTH SCIENCES	MEDICAL CENTER BLVD	WINSTON SALEM	NC	27157	FORSYTH	USA	Cancer Treatment Research	000	1	12/10/2021	NEW	$217,388
														Subtotal = $217,388

Grand Total All Awards = $394,922

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeted Anchoring Ecto-enzyme on Cancer Cell Surface to Enhance Antibody Therapy in Breast Cancer

Award Number: R21CA267853

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/10/2021

PERIOD OF PERFORMANCE END DATE: 05/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer